Lewy bodies

Lewy bodies. They are abnormal, spherical protein aggregates found within the nerve cells of the brain, representing a primary pathological hallmark of several neurodegenerative disorders. First identified in the early 20th century, their presence is intimately linked to progressive cognitive decline, motor dysfunction, and psychiatric symptoms. The study of these inclusions has become central to understanding a spectrum of conditions now known as synucleinopathies.

Definition and discovery

The defining feature was first described in 1912 by the German neurologist Friedrich H. Lewy while he was working in the laboratory of Alois Alzheimer in Munich. Lewy observed these unusual inclusions in the basal ganglia and brainstem of patients with parkinsonism. For decades, their significance was overshadowed by the more widely recognized pathology of Alzheimer's disease, until critical re-evaluations in the latter half of the 20th century. The seminal work of Kosaka Kenji in Japan during the 1970s and 1980s was instrumental in linking their presence in the cerebral cortex to a distinct form of dementia, leading to the formalization of dementia with Lewy bodies as a diagnostic entity.

Composition and structure

The primary structural component is the protein alpha-synuclein, which aggregates into insoluble fibrils under pathological conditions. Other proteins commonly found within these inclusions include ubiquitin, neurofilament proteins, and components of the ubiquitin-proteasome system. Ultrastructurally, they appear as dense spherical cores surrounded by a radiating halo of filamentous material when viewed under electron microscopy. Their formation is thought to involve a cascade of molecular events including misfolding, phosphorylation, and fibrillization of alpha-synuclein, a process that may be influenced by genetic mutations in genes like SNCA and GBA.

Associated diseases

They are the defining pathological lesion of Parkinson's disease, where they are predominantly found in the substantia nigra and other brainstem nuclei. Their presence in the neocortex and limbic system is the core criterion for dementia with Lewy bodies, a condition that shares clinical features with both Parkinson's disease dementia and Alzheimer's disease. Furthermore, they are found in most cases of pure autonomic failure and in a subset of individuals with multiple system atrophy, the latter also characterized by glial cytoplasmic inclusions. The collective term for these disorders is synucleinopathy.

Pathophysiology

The accumulation of these protein aggregates is believed to disrupt critical cellular processes, leading to neuronal dysfunction and death. Proposed mechanisms include impairment of the ubiquitin-proteasome system and autophagy-lysosomal pathway, which are responsible for clearing damaged proteins. Their presence is associated with mitochondrial dysfunction, oxidative stress, and synaptic damage, particularly affecting neurotransmitters like dopamine and acetylcholine. The spread of pathological alpha-synuclein throughout the brain may follow a prion-like propagation, traveling along neural pathways from the brainstem to the cerebral cortex.

Diagnosis and detection

Definitive diagnosis historically required postmortem examination of brain tissue, typically stained with antibodies against alpha-synuclein or ubiquitin. Antemortem clinical diagnosis relies on consensus criteria established by groups like the Consortium on Dementia with Lewy Bodies and the Movement Disorder Society, which emphasize core features such as fluctuating cognition, visual hallucinations, and parkinsonism. Advanced neuroimaging techniques, including DaTscan (dopamine transporter scan) and FDG-PET, can support the diagnosis by revealing patterns of reduced dopaminergic activity or metabolic changes. Polysomnography is often used to detect REM sleep behavior disorder, a strong predictive marker.

Research and treatment

Current research focuses on understanding the triggers of protein aggregation and developing disease-modifying therapies. Promising avenues include immunotherapy targeting alpha-synuclein, small molecule inhibitors of aggregation, and gene therapies. Clinical trials are often coordinated through organizations like the Michael J. Fox Foundation and the Lewy Body Dementia Association. Symptomatic management remains multidisciplinary, utilizing medications such as cholinesterase inhibitors for cognitive symptoms and cautious use of levodopa for motor features, while avoiding typical antipsychotics due to severe sensitivity reactions. Supportive care involves physical therapy, occupational therapy, and caregiver education. Category:Neurology Category:Neuropathology